The global complicated urinary tract infections treatment market is on track to exceed expectations, with projections indicating a valuation surpassing US$ 9.2 billion in 2023 and a subsequent surge to US$ 16.1 billion by 2033. This growth trajectory, boasting a Compound Annual Growth Rate (CAGR) of 5.76%, is underpinned by various factors catalyzing advancements in diagnosis and treatment.
An integral driver of this remarkable growth is the advent of advanced diagnostic platforms, notably biosensors, which are revolutionizing the approach to UTI diagnosis. These cutting-edge biosensors offer unparalleled accuracy and efficiency, facilitating swift and precise detection of complicated UTIs. Moreover, the integration of biosensors with microfluidic technology for point-of-care applications is set to further streamline diagnosis processes, thereby bolstering market expansion.
Get Sample Copy of Latest Reports: https://www.futuremarketinsights.com/reports/sample/rep-gb-16486
Furthermore, the adoption of novel assays such as flow cytometry, MALDI-TOF mass spectrometry, fluorescence in situ hybridization, and multiplex PCR is significantly enhancing the diagnostic capabilities for complicated UTIs. These sophisticated assays not only enhance accuracy but also expedite the identification of causative pathogens, enabling prompt and targeted treatment interventions. Consequently, the incorporation of these innovative technologies is poised to fuel the growth of the global complicated UTIs treatment industry.
With the burgeoning prevalence of complicated UTIs worldwide, there is an urgent need for advanced diagnostic and treatment modalities. The remarkable growth forecast underscores the industry’s commitment to addressing this pressing healthcare challenge and underscores its pivotal role in improving patient outcomes globally.
Key Takeaways:
- North America is projected to lead the market of complicated urinary tract infections with an estimated market value of USD 5.29 billion by end of the forecast period.
- The market in East-Asia is expected to witness fastest CAGR of 5.1% while possessing 20% market share by end of 2033.
- By drug class, Penicillin and combinations is expected witness fastest segment growth of 7.9% during the forecast period.
- Quinolones segment is expected to possess hegemony with 48.6% market share by end of the forecast period.
- By distribution channel, hospital pharmacies is anticipated to dominate market with 51% market share by 2033.
Request Methodology Now: https://www.futuremarketinsights.com/request-report-methodology/rep-gb-16486
Competitive Landscape:
The global Complicated Urinary Tract Infections treatment market is highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition. The major players in the market are:
- Spero Therapeutics
- Wockhardt
- Venatorx Pharmaceuticals
- Allecra Therapeutics
- Nabriva Therapeutics AG
- MerLion Pharmaceuticals
- Allergan
- Bayer AG
- Pfizer, Inc
- GlaxoSmithKline plc
- Bristol-Myers Squibb Company
- Janssen Global Services, LLC
Some Recent Developments In This Industry Are:
- In November 2020, Allergan announced FDA acceptance of Supplemental New Drug Indication for Avycaz for the treatment of patients with complicated Urinary Tract Infections (cUTI) and complicated Intra-abdominal Infections (cIAI).
- In October 2021, Spero Therapeutics Inc. submitted a new drug application (NDA) to the US Food and Drug Administration (FDA), seeking approval for tebipenem HBr tablets for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible microorganisms.
- In September 2021, BDR Pharma, one of India’s leading generic pharmaceutical companies, launched biapenem to treat patients with intra-abdominal infections, lower respiratory infections, or complicated urinary tract infections.
Key Segments Profiled in the Complicated Urinary Tract Infections treatment Industry survey:
Complicated Urinary Tract Infections treatment market by Drug class:
- Penicillin and combinations
- Quinolones
- Cephalosporin
- Azoles and Amphotericin B
- Nitro furans
Complicated Urinary Tract Infections treatment market by Distribution channel:
- Hospital Pharmacies
- Gynecology and Urology Clinics
- Drug stores
- Retail Pharmacies
Complicated Urinary Tract Infections treatment market by Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa
Purchase Now to Access: https://www.futuremarketinsights.com/checkout/16486
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube